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ABSTRACT
Purpose To correlate the metabolic activity of primary
uveal melanoma on positron emission tomography (PET)/CT
scan with known clinical and pathological prognostic factors.
Methods A retrospective cohort analysis of eyes
enucleated for uveal melanoma that underwent preoperative
imaging with a PET/CT scan was performed. Tumour
dimensions were recorded and classiﬁed using Collaborative
Ocular Melanoma Study (COMS) and American Joint
Committee on Cancer (AJCC) Tumour - Nodes - Metastases
(TNM) criteria. Metabolic activity was determined by
measurement of the maximal standardised uptake value
(SUVmax) on PET/CT scans. SUVmax of >2.5 and >4 was
also used as cut-off value for metabolic positivity.
Chromosome 3 and 8 status was determined using
ﬂuorescence in situ hybridisation analysis. Pearson
correlation, χ2 test and non-parametric tests were used.
p<0.05 was considered statistically signiﬁcant.
Results Seventy-six uveal melanomas were imaged
preoperatively with a PET/CT scan. Overall 92% of tumours
had a SUVmax >2.5 and 67% had a SUVmax >4.
Monosomy 3 was found in 35 melanomas, of which 94%
had an SUVmax >2.5 and 80% had an SUVmax >4. Only
57% of disomy 3 melanomas had an SUVmax >4. SUVmax
was signiﬁcantly increased in tumours with monosomy 3
(p=0.043) but not in tumours with chromosome 8 gain
(p=0.49). SUVmax and increasing tumour size were
positively correlated (p<0.05). Using the AJCC criteria, there
was a signiﬁcant difference in SUVmax among prognostic
groups (p=0.024). There was no correlation with
histopathological cell type (p=0.923).
Conclusions Metabolic activity of uveal melanoma on
PET/CT scan is positively correlated with monosomy 3,
increasing tumour size and TNM prognostic groups. No
association with chromosome 8 gain or histopathology cell
type was noted. SUVmax >4 is a relative but not an
absolute indicator of monosomy 3 status.
INTRODUCTION
Uveal melanoma is the commonest primary intrao-
cular malignancy. Despite the availability of treat-
ment modalities, the survival rates have not changed
in 30 years. Cumulative rates of metastases in the
Collaborative Ocular Melanoma Study at 5 and
10 years after treatment were 25% and 34%,
respectively. Common sites of metastases include the
liver (90%), lung (24%) and bone (16%). Median
survival for a hepatic metastasis is 6 months with an
estimated survival of 15–20% at 1 year and 10% at
2 years, irrespective of treatment.1
Loss of one copy of chromosome 3 is associated
with a 5-year survival of approximately 50%,
whereas disomy 3 has been reported to predict
100% survival2 3 or less.4 These chromosomal
abnormalities, together with large tumour size and
epithelioid cell type, are established poor prognos-
tic risk factors.5
In recent years, dual-modality positron emission
tomography/CT (PET/CT) imaging has emerged as
an important staging modality for systemic malig-
nancies.6 Its advantage is the depiction of metabolic
activity as obtained by 18-ﬂuoro-2-deoxyglucose
PET in combination with detailed morphologic
characteristics from CT. Individual case series
have demonstrated that whole-body 18-ﬂuoro-2-
deoxyglucose tomography (18-FDG PET/CT)
imaging is sensitive in detecting hepatic and extra-
hepatic metastases in uveal melanoma patients.7–9
However, detection of primary choroidal melan-
oma has been reported to be dependent on tumour
size,10 11 status of chromosome 312 and histopath-
ology cell type.13
The aim of this study was to record the degree
of ocular metabolic activity seen on PET/CT scan-
ning in patients undergoing primary enucleation
for uveal melanoma. The level of metabolic activity
(maximal standardised uptake value (SUVmax))
was correlated with the individual clinical, patho-
logical and cytogenetic features of each tumour.
MATERIALS AND METHODS
This work was approved by the Institutional
Review Board of Moorﬁelds Eye Hospital. The
clinical records of all patients that underwent
primary enucleation for uveal melanoma between
2009 and 2012 were reviewed. Tumour dimensions
(thickness, maximal and minimal base diameter)
and anatomic location were recorded with fundus
examination and B-scan ocular ultrasound (Acuson
Sequoia 512—Siemens AG, Munich, Germany)
(ﬁgure 1). Uveal melanoma size was classiﬁed
according to the American Joint Committee on
Cancer (AJCC) 7th edition system and the
Collaborative Ocular Melanoma Study (COMS)
criteria. Tumour area and volume were calculated
as previously described.9
All patients were staged with a PET/CT scan
(Philips Gemini TF LSO64) (ﬁgure 1). Images used
in visual and region of interest (ROI) analysis were
acquired in three-dimensional and reconstructed
using OSEM (ordered subset expectation maximisa-
tion; 33 subsets, three iterations, no ﬁlters). All
patients fasted for 6 h and the uptake time was
60 min. Half-body imaging was acquired in 10 or
11 bed positions from skull base to thighs. The CT
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scan for attenuation correction and anatomical localisation was
performed at 120 Kvp and 60 mAs. Additional views of the
head and neck were acquired at the end to minimise effects of
patient movement. All PET/CT images were evaluated for areas
of increased ﬂuorodeoxyglucose uptake (SI and TS). If ﬂuoro-
deoxyglucose uptake was identiﬁed at the site of the melanoma,
the SUVs were derived from ROI drawn on contiguous axial
slices encompassing the entire lesion and by SUVmax that was
localised to the area of tumour seen clinically. SUV provides an
index of tracer uptake that can be compared between scans. It
provides a semiquantitative measure of tracer uptake and is
based on the approximation that the tracer is uniformly distribu-
ted throughout the body, hence normal tissue SUV is approxi-
mately=1
SUV ¼ tracer uptake (inMBq=mL) 1000
Administered activity (MBq)=Patientweight (kg)
Following enucleation, a fresh tumour tissue sample was
obtained with a punch biopsy with a 6 mm trephine. Biopsy
samples were manually disaggregated and aspirate samples cen-
trifuged at 1200 rpm to remove transport medium prior to
preparation of slides. The samples were incubated in 0.075 M
KCl for 15 min and then ﬁxed with methanol to acetic acid
(3:1). Interphase ﬂuorescence in situ hybridisation (FISH) was
performed using three DNA probes (CEP3 SpectrumOrange to
CEN 3, Vysis, Des Plaines, Illinois, USA), speciﬁc for the centro-
mere region of chromosome 3 (3p11.1-q11.1) and (LSI IGH/
MYC, CEP8 triple colour, dual fusion probe, Vysis, Des Plaines,
Illinois, USA), for the centromere region of chromosome 8
(8p11.1-8q11.1), MYC (8q24) and IGH@ (14q32, used as a
control) according to the manufacturer’s protocol (Abbott
Laboratories, Downers Grove, Illinois, USA). Slides were coun-
terstained with 4060Diamidino-2-phenylindole dihydrochloride
(DAPI) (Invitrogen). For each probe set, a total of 100 non-
overlapping nuclei were analysed by two independent analysts
using a ﬂuorescence microscope (Zeiss Axio Imager M1)
equipped with dual and triple ﬁlters. Representative images
were captured and stored using the Isis colour ﬂuorescence and
FISH imaging system (Metasystems, Germany). A cut-off limit
for the detection of monosomy of chromosome 3 was 10%, and
the cut-off limit for the detection of ampliﬁcation of chromo-
some 8 was 5%. All karyotypes were described according to the
International System for Human Cytogenetic Nomenclature.14
The removed globe was sent for histopathology reporting.
Melanoma was classiﬁed as spindle A or B, mixed or epithelioid.
The presence of retinal detachment, haemorrhage, necrosis and
inﬂammatory inﬁltration was recorded.
Statistical analysis
Statistical analysis was performed using statistical software (SPSS
V.13.0). Descriptive statistics were used to evaluate tumour fea-
tures. The relationship between tumour metabolic activity
(SUVmax) and tumour dimension was determined with
Pearson’s correlation coefﬁcient. Previously published cut-off
indices (>2.5 and >4) for SUVmax were also used in the evalu-
ation of data.10 χ2 test was used to determine any statistically
signiﬁcant difference between the groups according to the pub-
lished SUVmax cut-off values. Correlation with tumour loca-
tion, histopathology and cytogenetic status was determined with
the Mann–Whitney and Kruskal–Wallis tests. A p value of
>0.05 was considered to be statistically signiﬁcant.
RESULTS
Seventy-six eyes were included in the study (table 1). All
tumours were detectable and measurable on PET/CT scan.
SUVmax values had a signiﬁcantly positive correlation with
tumour thickness (r=0.368, p=0.001, Pearson’s correlation
coefﬁcient) (ﬁgure 2A), area (r=0.241, p=0.036) (ﬁgure 2B)
and volume (r=0.36, p=0.001) (ﬁgure 2C). No correlation was
noted with maximal base diameter (r=0.181, p=0.117) or
tumour location (p=0.2, Kruskal–Wallis test). Using the AJCC
Figure 1 Top row: fundus
photograph of a large left amelanotic
choroidal melanoma. Choroidal vessels
are discernible with an associated
superﬁcial haemorrhage and retinal
detachment. Ultrasound scan indicated
a mushroom shaped lesion measuring
7.5 mm. Bottom row: the composite of
CT scan and positron emission
tomography (PET) scan demonstrates
the anatomic location and metabolic
ﬂuoro-2-deoxyglucose tomography
uptake of the melanoma.
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Table 1 Patient demographics, tumour data and corresponding SUVmax values
SUVmax
median (mean±SD) (range) p Value (test)*
Total number of patients 76 5.45 (6.35±3.5) (2–15.9)
Male 46/76 (60.5%)
Female 30/75 (39.5%)
Tumour dimensions
Median (mean±SD) (range)
Tumour thickness (mm) 10 (10.1±2.5) (4.7–15.9)
Maximal base diameter (mm) 15 (14.7±3.2) (4.5–20.3)
Area (mm2) 143 (147.4±58.08) (23.7–287.7)
Volume (mm3) 942 (1040.9±570) (87–2546)
COMS classification†
Medium melanomas 12/76 (15.8%)
Large melanomas 64/76 (84.2%)
AJCC classification
IIA (T1b-d and T2a N0 M0) 4/76 (5.3%) 3 (2.9±0.6) (2.2–3.6) 0.024 (Kruskal–Wallis test)
IIB (T2b and T3a N0 M0) 30/76 (39.5%) 4.9 (5.3±2.79) (2.1–13.2)
IIIA (T2c-d and T3b-c and T4a N0 M0) 27/76 (35.5%) 6.5 (7.1±3.8) (2–14.7)
IIIB (T3d and T4b-c N0 M0) 13/76 (17.1%) 7.1 (7.9±3.7) (3.4–15.9)
IIIC (T4d-e N0 M0) 2/76 (2.6%) 7.4 (7.4±5.09) (3.8–11)
Tumour location
Ciliary body 11/76 (18%) 7 (7.4±3.2) (3.6–13.3) 0.2 (Kruskal–Wallis test)
Ciliochoroidal 30/76 (41%) 6 (6.8±3.9) (2–15.9)
Choroidal 35/76 (48%) 5 (5.4±2.8) (2.1–13.2)
Histopathology‡
Epithelioid 13/75 (17.3%) 6.4 (6.7±3.6) (2.3–14.7) 0.923 (Kruskal–Wallis test)
Spindle A 31/75 (41.3%) 5.2 (6.3±3.5) (2.1–14.7)
Spindle B 4/75 (5.3%) 5.3 (6.3±3.6) (2–15.9)
Mixed 27/75 (36%) 4.1 (5.1±2.7) (3.2–9.1)
High risk 35/75 (46.6%) 5.7 (6.4±3.5) (2.1–14.7) 0.687
Low risk 40/75 (53.3%) 4.9 (6.2±3.6) (2–15.9)
Pathology features
Necrosis 6/76 (8%) 5.6 (6.9±3.6) (3.1–13.3) 0.61
No necrosis 70/76 (92%) 5.4 (6.3±3.5) (2–15.9)
Inflammation 13/76 (17%) 6.4 (6.6±4.4) (2.1–14.2) 0.82
No inflammation 63/76 (83%) 5.3 (6.3±3.3) (2–15.9)
Retinal detachment 46/76 (60.5%) 6.3 (6.8±4.8) (2–15.9) 0.15
No retinal detachment 30/76 (39.5%) 4.7 (5.5±2.9) (2.1–14.2)
Haemorrhage 10/76 (13%) 4 (5.8±3.8) (2.8–14.7) 0.56
No haemorrhage 66/76 (87%) 5.7 (6.4±3.5) (2–15.9)
Cytogenetic analysis§
Chromosome 3
Monosomy 3 35/73 (47.9%) 6.5 (7±3.3) (2–15.9) 0.043
Disomy 3 35/73 (47.9%) 4.3 (5.6±3) (2.2–14.7)
Failure 3/73 (4%) 0.49
Chromosome 8
Gain of 8 52/73 (71.2%) 6.3 (6.1±3) (2–15.9)
Disomy 8 18/73 (24.7%) 4.1 (6.2±4.2) (2.4–14.7)
Failure 3/73 (4%)
Monosomy 3/gain of 8 33/73 (45%) 6.55 (7.2±3.2) (2–15.9)
Monosomy 3/disomy 8 2/73 (2.7%) 2.45 (2.45±0.5) (2.1–2.8) 0.015¶
Disomy 3/gain of 8 19/73 (26%) 4.3 (5.1±3.1) (2.2–14.2)
Disomy 3/disomy 8 16/73 (22%) 4.2 (6.3±4) (2.7–14.7) 0.354
*Mann–Whitney test unless noted.
†Small melanoma (1.5–2.4 mm in thickness and 5–16 mm in diameter), medium melanoma (2.5–10 mm in thickness and ≤16 mm in diameter) and large melanoma (>10 mm in
thickness and >16 mm in diameter).
‡Available in 75 tumours.
§Available in 73 tumours.
¶Versus disomy 3/gain 8.
AJCC, American Joint Committee on Cancer; COMS, Collaborative Ocular Melanoma Study; SUVmax, maximal standardised uptake value.
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classiﬁcation (table 1), there was a statistically signiﬁcant differ-
ence among prognostic groups (p=0.024, Kruskal–Wallis test).
Analyses are presented in detail in ﬁgure 3. Groups IIIA and
IIIB had signiﬁcantly higher SUVmax in comparison to other
groups. Interestingly, in the COMS classiﬁcation, no signiﬁcant
difference was noted between groups (p=0.161, Mann–
Whitney test). SUVmax >2.5 was noted in 70/76 (92%) and
SUVmax >4 was noted in 51/76 (67%) of examined tumours.
Cytogenetic analysis was performed on 73 tumours (table 1).
SUVmax values were signiﬁcantly higher in monosomy 3 com-
pared with disomy 3 tumours (p=0.043, Mann–Whitney test)
(table 1, ﬁgure 4A). There was no signiﬁcant difference in thick-
ness (p=0.7), area (p=0.95) or volume (p=0.88, Mann–
Whitney test) between groups. A SUVmax of >2.5 was noted in
33/35 (94%) of tumours with monosomy 3 and 32/35 (91.5%)
of tumours with disomy 3 (χ2, p=0.8). A SUVmax >4 was noted
in 28/35 (80%) monosomy 3 tumours and 20/35 (57%) of
disomy 3 tumours (χ2, p=0.06). Based on analysis of the cut-off
valve, SUVmax >4 is better at predicting a monosomy 3 tumour
than a SUVmax >2.5, but this was not statistically signiﬁcant.
With regard to status of chromosome 8, no signiﬁcant differ-
ence was noted in SUVmax (p=0.49, Mann–Whitney test)
(table 1, ﬁgure 4B). SUVmax >2.5 was noted in 51/55 (92.7%)
of tumours with gains in chromosome 8 and 17/18 (94.4%)
with the normal diploid component (χ2, p=0.6). SUVmax >4
was noted in 41/55 (74.5%) and 13/18 (72%) in each group
(χ2, p=0.06).
When chromosome status was assessed collectively (table 1),
the coexistence of monosomy 3 and gains in chromosome 8 was
associated with signiﬁcantly higher SUVmax when compared
against tumours with disomy 3 and gains in chromosome 8
(p=0.015, Mann–Whitney test). SUVmax >2.5 was noted in
33/34 (97%) of tumours with monosomy 3/gain of chromosome
8 and 15/15 (100%) of tumours with normal diploid
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Figure 2 Correlation of maximal standardised uptake value (SUVmax) with tumour dimensions. Signiﬁcant positive correlation of SUVmax with
thickness (A) (r=0.368, n=75, p=0.001, Pearson’s correlation coefﬁcient), area (B) (r=0.241, n=76, p=0.036, Pearson’s correlation coefﬁcient) and
volume (C) (r=0.36, n=75, p=0.001, Pearson’s correlation coefﬁcient) are depicted. [Area (a) (mm2) π (d1+d2/4)
2 and volume (mm3) 2/3a×h].
Figure 3 Maximal standardised uptake value (SUVmax) (mean±SE)
in different prognostic groups (numerical values in table 1).
(*) Statistically signiﬁcant difference of IIIA versus IIA (p=0.04).
(**) Statistically signiﬁcant difference of IIIB versus IIA (p=0.002),
versus IIB (p=0.014) (Mann–Whitney test).
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component (χ2, p=0.694). A SUVmax >4 was noted in 29/34
(85.3%) and 9/15 (60%), respectively (χ2, p=0.06). SUVmax
>4 was therefore better in this context than SUVmax >2.5 to
associate metabolic uptake with high-risk chromosome status
though this was again not statistically signiﬁcant.
Histopathology cell type was available on 75 enucleated eyes
(table 1). SUVmax did not correlate with cell type (p=0.923,
Kruskal–Wallis test). In addition, no correlation with SUVmax
was noted when cell types were qualiﬁed as high risk (epithe-
lioid and mixed, 40/75 (53.3%)) versus low risk (spindle A
and B, 35/75 (46.6%)) (p=0.687, Mann–Whitney test) (table 1,
ﬁgure 4C, D). There were no dimensional differences among
histopathology cell types (p=0.78 for thickness, p=0.83 for
volume, p=0.55 for area, Kruskal–Wallis test).
Tumours with necrosis, inﬂammatory inﬁltration or haemor-
rhage did not have a signiﬁcantly different SUVmax (table 1,
ﬁgure 4E). Interestingly, melanomas with an associated detach-
ment did present with a considerable although non-signiﬁcantly
higher uptake (p=0.15, Mann–Whitney test).
DISCUSSION
PET/CT scan in ophthalmic oncology has demonstrated high
sensitivity and a positive predictive value for liver metastases in
patients with primary uveal melanoma.7 In addition, PET/CT
has been shown to improve the detection of extrahepatic metas-
tases or synchronous primary cancers.7 11 In the London Ocular
Oncology service, PET/CT scans are routinely used in staging
melanoma patients scheduled for enucleation. It is not
Figure 4 (A–E). Maximal standardised uptake value (SUVmax) correlation with assessed parameters. Number of patients in each group denoted
on bar. (A) SUVmax was signiﬁcantly higher in melanomas with monosomy 3 versus tumours with normal diploid component (p=0.04, Mann–
Whitney test). (B) No signiﬁcant difference with regards to chromosome 8 status (p=0.49, Mann–Whitney test). (C, D) SUVmax correlation with
histopathology cell type and histopathology features in uveal melanoma. (C) No signiﬁcant difference noted between high-risk (epithelioid and
mixed) and low-risk (spindle A and B) uveal melanomas (p=0.687, Mann–Whitney test). (D) Similar results noted among speciﬁc histopathology cell
types (p=0.923, Kruskal–Wallis test). (E) No signiﬁcant difference noted in SUVmax in lesions with or without necrosis, inﬂammation, detachment or
haemorrhage (Mann–Whitney test, p values on chart).
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recommended as a surveillance investigation because of the sig-
niﬁcant radiation-related cancer risk.15 The evaluation of uveal
melanoma with PET/CT scan has been implicated as a prognos-
tic tool in individual case series, and the metabolic uptake was
recorded qualitatively13 or semiquantitatively with SUVmax or
SUVmean.10 12 16–18 The aim of this study was to examine the
correlation of metabolic activity against clinical, cytogenetic and
histopathological factors. In this study, absolute SUVmax values
were primarily used. In addition, cut-off values of >2.5 or >4
were also used to categorise a ‘positive’ SUVmax as previously
reported.10 12 17 The selection of these cut-off values has not
been standardised.
Chromosome 3 monosomy in uveal melanoma is a commonly
used predictor of mortality.2 3 5 Disomy of chromosome 3 has a
protective effect, but recent data indicate that the presence of
the SF3B1 mutation on chromosome 3 might be associated with
increased mortality.4 Additional abnormalities in chromosomes
1, 6 and 8 have also been considered as prognostic factors.19
Cytogenetic information is usually obtained by ﬁne needle aspir-
ation biopsy. PET/CT is a non-invasive investigation, which may
be able to provide important prognostic information without
the need for a biopsy.
To date, there is only one other publication supporting the
association between SUVmax and loss of chromosome 3.
McCannel et al12 analysed 37 uveal melanomas and concluded
that cases with SUVmax >2.5 correlated positively with loss of
chromosome 3. FISH analysis was used to record loss of
chromosome 3; however, the cut-off percentage to determine
monosomy 3 was not reported. In this study, 13/37 (35%)
patients were found to have loss of chromosome 3 and of these,
7/13 (54%) had a SUVmax >2.5. All of the disomy 3 tumours
had a SUVmax <2.5. Of note, the seven tumours with positive
SUVmax and chromosome 3 loss were signiﬁcantly larger. We
found that SUVmax values increase with tumour dimensions,
and this is likely to be a confounding factor in their data.
In our study, 35 of 73 patients were found to have monosomy
3 on FISH analysis using a cut-off of 10% of cells affected to
determine chromosome status. The FISH technique was done
under optimal conditions using a fresh tissue biopsy from
tumour. It should be noted that other techniques have yielded
superior results in the detection of monosomy 3.20 SUVmax
was signiﬁcantly higher in patients with monosomy 3. The two
groups were of similar size (35 tumours each) and the tumour
thickness, area and volume were comparable. Our results also
show that SUVmax cut-off values cannot distinguish between
monosomy and disomy 3 melanoma; however, a higher
SUVmax of >4 was more helpful in determining monosomy 3
status.
Chromosome 8 status was also examined in order to deter-
mine any association with increased SUVmax. Gains in chromo-
some 8 are known to be associated with a poorer prognosis in
uveal melanoma.21 The presence of gains in chromosome 8 was
seen in 55 of 73 uveal melanomas. Gains in chromosome 8 did
not correlate with increased SUVmax values. The assessment of
combined chromosome expression further reinforces the afore-
mentioned results. Tumours with monosomy 3/gains in chromo-
some 8 had a signiﬁcantly higher SUVmax than disomy 3/gains
in 8 and a SUVmax >4 would be more helpful in identifying an
association with high-risk melanomas for chromosome 3/8
status.
Tumour size is important in the prognostication of choroidal
melanoma. Increased melanoma size has been shown to be dir-
ectly analogous to metastatic potential.22 In this study, both
standard classiﬁcation systems (AJCC and COMS) were used.
AJCC subgroups IIIA and IIIB were found to have signiﬁcantly
higher SUVmax uptake in comparison to other groups, conﬁrm-
ing the importance of tumour dimensions. In prior studies using
the COMS classiﬁcation, the tumour population has been het-
erogeneous with medium uveal melanoma represented in
7–36% and large uveal melanoma in 16–94%.8 10 12 16–18 Only
a few studies have included small melanomas.10 16 Our study
consisted of 16% medium and 84% large melanomas with no
small melanoma. Reddy et al measured the metabolic activity on
PET/CT in 18/50 (36%) small, 24/50 (48%) medium and 8/50
(16%) large uveal melanomas. Interestingly, none of the small
uveal melanomas had an SUVmax >2.5, but 75% of the large
tumours did, accounting for the low overall detection rate of
28%.10 In our study, 92% of uveal melanomas had an SUVmax
>2.5. This striking difference could be attributed to the larger
tumours in our series. The average resolution of a PET/CT
scanner is 4 mm, which may limit its ability to detect and
measure activity in small choroidal melanoma. Several publica-
tions have proven that SUVmax has a positive correlation with
tumour size.12 16 17 Our ﬁndings conﬁrmed this correlation
with regards to thickness and found an additional positive cor-
relation between SUVmax and increasing tumour volume.
Ciliary body melanoma is associated with poor survival.9
Tumours in this location tend to be larger and of mixed cell
type.22 23 A trend for an association with higher SUVmax and
anterior location has been implied in a case series of 14
patients17 though no correlation was found in a larger sample
size by the same group.10 In our study, there was no signiﬁcant
difference in SUVmax uptake among ciliary body, ciliochoroidal
or choroidal melanomas.
Uveal melanoma prognosis is also associated with tumour
pathology. Epithelioid and mixed cell tumours are considered as
high risk, and spindle cell melanomas are considered as low
risk.18 Previous studies23 have reported that 10-year mortality
ranged from 11% to 19% in spindle A tumours, 21–36% in
spindle B tumours, 63–79% in mixed-cell tumours and
72–100% in epithelioid tumours. In a case series of 14 uveal
melanomas, the SUVmean was signiﬁcantly increased in mixed
cell verses spindle cell tumours.16 Finger et al17 also reported a
trend for higher SUVmax in epithelioid tumours in 14 cases,
though this series had three epithelioid tumours one of which
had no uptake. On the other hand, a recent study of 34 melano-
mas18 did not yield a signiﬁcant difference for SUVmax among
different cell types. Our study supports the latter ﬁndings as no
such correlation was noted.
The presence of necrosis, inﬂammation or haemorrhage has
been reported to affect PET/CT uptake. Tumour necrosis has
been reported to be present in melanomas with high metabolic
uptake.13 Faia et al16 reported a signiﬁcant association of
SUVmean with necrosis and focal inﬂammation in 3/14 cases.
In our study, no signiﬁcant difference in SUVmax was found for
subgroups of patients with tumour necrosis (6/75, p=0.8) or
associated inﬂammation (13/75, p=0.8). This may be
because the number of tumours with these ﬁndings was small.
Retinal detachment at the time of diagnosis has been reported
as a risk factor for local recurrence and metastasis.24 In our
study, retinal detachment was present in 60% of melanomas
(46/76). The SUVmax was considerably higher in tumours with
a retinal detachment, but this was not statistically signiﬁcant
(p=0.1).
One practical limitation of our study is that the absolute
cut-off value for SUVmax to predict monosomy 3 status could
not be determined. This may be due to the known limitations of
FISH analysis or the fact that other chromosomes that impact
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on metabolic activity were not tested. It would be useful to use
gene expression proﬁling instead, which targets many more
chromosomes in uveal melanoma.
In conclusion, SUVmax as a measure of metabolic activity of
primary uveal melanoma on PET/CT scan may have prognostic
implications. SUVmax was conﬁrmed to have a signiﬁcant posi-
tive correlation with tumour size and monosomy 3 but did not
correlate with histological cell type or chromosome 8 status. To
our knowledge, this is the largest study that has examined the
correlation of SUVmax in primary uveal melanoma with known
clinical, histopathological and cytogenetic features. In addition,
this is the ﬁrst study to examine any association with chromo-
some 8 status. Our results suggest that the cut-off SUVmax
value of 2.5 used as an indicator of positive metabolic activity
cannot be used to distinguish between monosomy 3 and disomy
3 tumours. SUVmax >4, though not an absolute indicator,
might be more helpful in identifying monosomy 3 and gain of
chromosome 8 tumours.
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